23 result(s) found for: Cyclin D.
Displaying page 1 of 2.
| EudraCT Number: 2015-003892-31 | Sponsor Protocol Number: MedOPP089 | Start Date*: 2017-03-23 | |||||||||||
| Sponsor Name:Medica Scientia Innovation Research (MedSIR) | |||||||||||||
| Full Title: A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combina... | |||||||||||||
| Medical condition: Patients with hormone receptor (HR)-positive/HER2-negative locally advanced or metastatic breast cancer (mBC). Second/third-line of endocrine treatment. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-001965-41 | Sponsor Protocol Number: BRD/06/052 | Start Date*: 2008-09-05 |
| Sponsor Name:University College London | ||
| Full Title: Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma | ||
| Medical condition: Mantle Cell Lymphoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-001521-41 | Sponsor Protocol Number: UoL001304 | Start Date*: 2017-09-18 | |||||||||||
| Sponsor Name:University of Liverpool | |||||||||||||
| Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
| Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-002162-21 | Sponsor Protocol Number: JECF-VITD-2011-01 | Start Date*: 2012-04-24 |
| Sponsor Name:José Esteban Castelao Fernández | ||
| Full Title: A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer. | ||
| Medical condition: Women at high risk of developing breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-006177-32 | Sponsor Protocol Number: CC-5013-MCL-003 | Start Date*: 2010-01-06 | |||||||||||
| Sponsor Name:Celgene Corporation | |||||||||||||
| Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA | |||||||||||||
| Medical condition: Mantle-Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) FR (Completed) DE (Completed) ES (Completed) PT (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001040-62 | Sponsor Protocol Number: GBG78/BIG1-13 | Start Date*: 2013-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GBG Forschungs GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-005057-36 | Sponsor Protocol Number: GLG-801-07 | Start Date*: 2018-05-17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GLG Pharma S.A. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: PL (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-003435-13 | Sponsor Protocol Number: MARLENE | Start Date*: 2021-05-27 | |||||||||||
| Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
| Full Title: Metronomic vinorelbin, cyclophosphamide and capecitabine after progression to cyclin-dependent kinase 4/6 inhibitors for hormone receptors positive HER2 negative metastatic breast cancer | |||||||||||||
| Medical condition: HER2 negative hormone receptors positive metastatic breast cancer progressed after CDK 4/6 inhibitors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002324-36 | Sponsor Protocol Number: MK1026-003 | Start Date*: 2021-03-06 | |||||||||||||||||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies | |||||||||||||||||||||||||||||||||
| Medical condition: | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-000548-33 | Sponsor Protocol Number: LyMa101 | Start Date*: 2016-07-20 | |||||||||||
| Sponsor Name:LYSARC | |||||||||||||
| Full Title: Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven... | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000157-41 | Sponsor Protocol Number: UoL001343 | Start Date*: 2019-06-07 | |||||||||||
| Sponsor Name:The University of Liverpool | |||||||||||||
| Full Title: NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadj... | |||||||||||||
| Medical condition: ER-positive, HER2-negative breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002821-39 | Sponsor Protocol Number: MCLA-128-CL02 | Start Date*: 2017-11-13 | |||||||||||
| Sponsor Name:Merus N.V. | |||||||||||||
| Full Title: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive a... | |||||||||||||
| Medical condition: Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) PT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004039-30 | Sponsor Protocol Number: MCL5(MARiT) | Start Date*: 2012-04-03 | |||||||||||
| Sponsor Name:PLymouth Hospitals NHS Trust | |||||||||||||
| Full Title: Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years | |||||||||||||
| Medical condition: Mantle Cell Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001447-40 | Sponsor Protocol Number: 28UCS2019 | Start Date*: 2020-06-29 | ||||||||||||||||
| Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | ||||||||||||||||||
| Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | ||||||||||||||||||
| Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-002077-21 | Sponsor Protocol Number: ICR-CTSU/2017/10065 | Start Date*: 2019-04-18 | |||||||||||
| Sponsor Name:The Institute of Cancer Research | |||||||||||||
| Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth... | |||||||||||||
| Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005317-68 | Sponsor Protocol Number: ACE-CL-208 | Start Date*: 2016-05-16 | |||||||||||
| Sponsor Name:Acerta Pharma B.V. | |||||||||||||
| Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | |||||||||||||
| Medical condition: High Risk Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-001547-25 | Sponsor Protocol Number: ZILO-301 | Start Date*: 2023-04-04 | |||||||||||||||||||||
| Sponsor Name:Oncternal Therapeutics, Inc | |||||||||||||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects with Relapsed or Refractory Ma... | |||||||||||||||||||||||
| Medical condition: Relapsed or Refractory Mantle Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2020-005591-35 | Sponsor Protocol Number: INCMOR0208-101 | Start Date*: 2021-06-30 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti-CD19 Monoclonal Antibody Tafasitamab and the PI3K delta Inhibito... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) IT (Completed) ES (Temporarily Halted) AT (Completed) BE (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-001087-10 | Sponsor Protocol Number: ELA-0121 | Start Date*: 2022-11-21 | |||||||||||
| Sponsor Name:Stemline Therapeutics, Inc | |||||||||||||
| Full Title: An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative B... | |||||||||||||
| Medical condition: Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001648-24 | Sponsor Protocol Number: MedOPP321_ABIGAIL | Start Date*: 2021-06-23 | |||||||||||
| Sponsor Name:MEDICA SCIENTIA INNOVATION RESEARCH S.L. | |||||||||||||
| Full Title: randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as f... | |||||||||||||
| Medical condition: Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease crite... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
